Article

Activation of PP2A-B56α leads to aberrant EGFR signaling and proliferative phenotypes in PDAC

2025-07-19

Abstract excerpt

<h4>ABSTRACT</h4> Pancreatic ductal adenocarcinoma (PDAC) stands to become the second most deadly cancer by 2030. The small GTPase, KRAS, is mutated in over 90% of PDAC patients and considered the primary driver mutation. Despite being an almost ubiquitous event, KRAS mutations have been difficult to target therapeutically, particularly KRAS G12D , the most common mutation in PDAC. In addition to these pharmacol...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 3111b25d-d6c8-59b3-b1b3-2cd7bd220104
DOI: 10.1101/2025.07.18.665598

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Activation of PP2A-B56α leads to aberrant EGFR signaling and proliferative phenotypes in PDACDOI 10.1101/2025.07.18.665598Read

KRAS-mediated upregulation of CIP2A promotes suppression of PP2A-B56α to initiate pancreatic cancer developmentSemantic proximity Read

Altered PI3K and ERK/MAPK Signaling in KRASG12R-Driven Pancreatic Cancer Presents Opportunities for Precision Therapy.Semantic proximity Read

KRAS-Driven Tumorigenesis and KRAS-Driven Therapy in Pancreatic Adenocarcinoma.Semantic proximity Read

Oncogenic KRAS signalling in pancreatic cancerSemantic proximity Read

KRAS: the Achilles' heel of pancreas cancer biology.Semantic proximity Read

Molecular dissection of pancreatic cancer signaling: Toward targeted therapies for KRAS, MDM2-TP53, EGFR, and PI3K/AKT/mTOR.Semantic proximity Read

KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities.Semantic proximity Read

Emerging Therapeutic Landscapes for KRAS-Mutant Pancreatic Ductal Adenocarcinoma: Beyond the "Undruggable" Paradigm.Semantic proximity Read

Targeting KRAS mutations in pancreatic cancer: opportunities for future strategiesSemantic proximity Read

Key Considerations for Targeting KRAS in Pancreatic Cancer: Potential Impact on the Treatment Paradigm.Semantic proximity Read

The protein phosphatase-2A subunit PR130 is linked to cytotoxic protein aggregate formation in mesenchymal pancreatic ductal adenocarcinoma cellsSemantic proximity Read

KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progressionSemantic proximity Read